Artificial intelligence technology has made its way absolutely necessary in a variety of industries including the fitness industry. Human pose estimation is one of the important researches in the field of Computer Vision for the last few years. In this project, pose estimation and deep machine learning techniques are combined to analyze the performance and report feedback on the repetitions of performed exercises in real-time. Involving machine learning technology in the fitness industry could help the judges to count repetitions of any exercise during Weightlifting or CrossFit competitions.

Fact-based dialogue generation is a task of generating a human-like response based on both dialogue context and factual texts. Various methods were proposed to focus on generating informative words that contain facts effectively. However, previous works implicitly assume a topic to be kept on a dialogue and usually converse passively, therefore the systems have a difficulty to generate diverse responses that provide meaningful information proactively. This paper proposes an end-to-end Fact-based dialogue system augmented with the ability of convergent and divergent thinking over both context and facts, which can converse about the current topic or introduce a new topic. Specifically, our model incorporates a novel convergent and divergent decoding that can generate informative and diverse responses considering not only given inputs (context and facts) but also inputs-related topics. Both automatic and human evaluation results on DSTC7 dataset show that our model significantly outperforms state-of-the-art baselines, indicating that our model can generate more appropriate, informative, and diverse responses.

We identify the structure of the lexicographically least word avoiding 5/4-powers on the alphabet of nonnegative integers. Specifically, we show that this word has the form $p au(varphi(z) varphi^2(z) cdots)$ where $p, z$ are finite words, $varphi$ is a 6-uniform morphism, and $ au$ is a coding. This description yields a recurrence for the $i$th letter, which we use to prove that the sequence of letters is 6-regular with rank 188. More generally, we prove $k$-regularity for a sequence satisfying a recurrence of the same type.

We propose some new mixed finite element methods for the time dependent stochastic Stokes equations with multiplicative noise, which use the Helmholtz decomposition of the driving multiplicative noise. It is known [16] that the pressure solution has a low regularity, which manifests in sub-optimal convergence rates for well-known inf-sup stable mixed finite element methods in numerical simulations, see [10]. We show that eliminating this gradient part from the noise in the numerical scheme leads to optimally convergent mixed finite element methods, and that this conceptual idea may be used to retool numerical methods that are well-known in the deterministic setting, including pressure stabilization methods, so that their optimal convergence properties can still be maintained in the stochastic setting. Computational experiments are also provided to validate the theoretical results and to illustrate the conceptional usefulness of the proposed numerical approach.

We study the problem of jointly designing a sparse sensor and actuator schedule for linear dynamical systems while guaranteeing a control/estimation performance that approximates the fully sensed/actuated setting. We further prove a separation principle, showing that the problem can be decomposed into finding sensor and actuator schedules separately. However, it is shown that this problem cannot be efficiently solved or approximated in polynomial, or even quasi-polynomial time for time-invariant sensor/actuator schedules; instead, we develop deterministic polynomial-time algorithms for a time-varying sensor/actuator schedule with guaranteed approximation bounds. Our main result is to provide a polynomial-time joint actuator and sensor schedule that on average selects only a constant number of sensors and actuators at each time step, irrespective of the dimension of the system. The key idea is to sparsify the controllability and observability Gramians while providing approximation guarantees for Hankel singular values. This idea is inspired by recent results in theoretical computer science literature on sparsification.

With the growing reliance on the ubiquitous availability of IT systems and services, these systems become more global, scaled, and complex to operate. To maintain business viability, IT service providers must put in place reliable and cost efficient operations support. Artificial Intelligence for IT Operations (AIOps) is a promising technology for alleviating operational complexity of IT systems and services. AIOps platforms utilize big data, machine learning and other advanced analytics technologies to enhance IT operations with proactive actionable dynamic insight.

In this paper we share our experience applying the AIOps approach to a production cloud object storage service to get actionable insights into system's behavior and health. We describe a real-life production cloud scale service and its operational data, present the AIOps platform we have created, and show how it has helped us resolving operational pain points.

Behavioral research can provide important insights for SE practices. But in performing it, many studies of SE are committing a normative fallacy - they misappropriate normative and prescriptive theories for descriptive purposes. The evidence from reviews of empirical studies of decision making in SE suggests that the normative fallacy may is common. This article draws on cognitive psychology and behavioral economics to explains this fallacy. Because data collection is framed by narrow and empirically invalid theories, flawed assumptions baked into those theories lead to misleading interpretations of observed behaviors and ultimately, to invalid conclusions and flawed recommendations. Researchers should be careful not to rely solely on engineering methods to explain what people do when they do engineering. Instead, insist that descriptive research be based on validated descriptive theories, listen carefully to skilled practitioners, and only rely on validated findings to prescribe what they should do.

We develop a categorical compositional distributional semantics for Lambek Calculus with a Relevant Modality !L*, which has a limited edition of the contraction and permutation rules. The categorical part of the semantics is a monoidal biclosed category with a coalgebra modality, very similar to the structure of a Differential Category. We instantiate this category to finite dimensional vector spaces and linear maps via "quantisation" functors and work with three concrete interpretations of the coalgebra modality. We apply the model to construct categorical and concrete semantic interpretations for the motivating example of !L*: the derivation of a phrase with a parasitic gap. The effectiveness of the concrete interpretations are evaluated via a disambiguation task, on an extension of a sentence disambiguation dataset to parasitic gap phrase one, using BERT, Word2Vec, and FastText vectors and Relational tensors.

Graphic design is everywhere — it’s used in traditional marketing efforts like billboards and fliers, and more importantly, it’s used in nearly every single digital marketing initiative from web design to social media marketing. If you’re a business that’s working with a digital marketing agency for any number of marketing campaigns (especially web design), it’s […]

The post 24 Must-Know Graphic Design Terms appeared first on WebFX Blog.

When you bookmark pages on the web, it’s challenging to remember the name of the page. As you dive back into your bookmarks to find it, you see a small icon next to the page. You recognize the icon and realize it’s the website you viewed prior. This icon, known as a favicon, is small, […]

The post What is a Favicon? [+4 Tips for Creating an Impactful Favicon] appeared first on WebFX Blog.

I am back in the collecting game. After several months of work and keeping an eye on deals, I am now inching closer toward 100 titles and have built a pretty nice 4K UHD collection. It started with my first DVD…

ON INLANDER.COM NATION: For workers, there's no sign of what "normal is going to look like" in the pandemic economy.…

The present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.

The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group,W is a group of formula —NH—SO2—R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

Provided are triazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

The present invention provides 4,6-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

A rubber composition for manufacturing tyres is based on one or more diene elastomers, one or more reinforcing fillers, and a vulcanization system. The vulcanization system includes one or more 1,2,4-triazine compounds chosen from compounds of formula I and compounds of formula II: Certain specific 1,2,4-triazine derivatives are described.

1,4-Dihydropyridine-3-carboxylate derivatives are produced having vasodilating and hypotensive action.

Disclosed is a process for preparing bridged Group 4 metal complexes containing a neutral diene ligand starting from the corresponding novel, metal diene containing complexes by reaction thereof with the divalent derivative of a bridged bidentate ligand compound. The novel, intermediate metal diene complexes, their formation from tetravalent metal salts and an integrated process combining both process steps are claimed.

1,4 fullerene deriatives useful for solar cells are provided, where their structures allow for straightforward functionalizations to tune their properties in terms of solubility and LUMO energy levels.

The present invention primarily concerns certain 4-alkyl pyridines of the following formula (I), wherein R is C8-C12 alkyl, odiferous substance mixtures and aromatic substance mixtures containing these 4-alkyl pyridines, the respective uses thereof as an odiferous or aromatic substance (mixture) and corresponding perfumed products.

A compound and a fragrance composition containing the same are provided, wherein the compound has a citrus odor in addition to a muguet odor, which is useful as a fragrance, is stable in an aqueous vehicle, and can provide a bright muguet odor with good fragrance retention by being blended with another fragrance. Particularly, they are 4(3)-(4-hydroxy-4-methylpentyl)-3-cyclohexene-1-carbonitrile and a fragrance composition containing 4(3)-(4-hydroxy-4-methylpentyl)-3-cyclohexene-1-carbonitrile.

A method for isolating 2,2,4,4-tetramethyl-1,3-cyclobutanediol (TMCD) solids from an isolated feed slurry formed in a TMCD process comprising TMCD, a liquid phase, and impurities by (a) treating the isolated feed slurry in a product isolation zone to produce an isolated TMCD product wet cake, a mother liquor, and impurities; wherein the product isolation zone can comprise at least one rotary pressure drum filter.

A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

A process for producing a purified O-(2,6-dichloro-4-methylphenyl)-O,O-dimethyl phosphorothioate, the process comprising: the first step of bringing a crude O-(2,6-dichloro-4-methylphenyl)-O,O-dimethyl phosphorothioate into contact with an acid; andthe second step of recovering the purified O-(2,6-dichloro-4-methylphenyl)-O,O-dimethyl phosphorothioate from the mixture obtained in the first step.

A method of preparing the anthracyclin carminomycin using a starting material comprising daunorubicin. The method comprises reacting daunorubicin or N-protected daunorubicin with soft Lewis acids for the demethylation of the 4-methoxy group, resulting in a reaction mass. The reaction mass is treated with an aqueous solution of a strong organic acid or a mineral acid. After decomposition of the resulting carminomycin and Lewis acids reactive complex, the reaction mass is extracted using a water insoluble organic solvent. As a result, carminomycin is extracted as a base.

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target SMAD4 gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating anemia of inflammation in humans).

The present invention is directed to L-proline and citric acid co-crystals of (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, pharmaceutical compositions containing said co-crystals and their use in the treatment glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.

The present invention relates to the field of cardiology. More specifically, the present invention provides methods and compositions for inducing proliferation of cardiomyocytes. In a specific embodiment, a method for inducing proliferation of cardiomyocytes comprises the step of administering an effective amount of an ALMS1 inhibitor.

Method for preparing diamino-dianhydro-dideoxyhexitols, particularly 2,5-diamino-1,4:3,6-dianhydro-2,5-dideoxy-D-hexitol. The invention related to a method for preparing diamino-dianhydro-dideoxyhexitols, particularly preferably 2,5-diamino-1,4:3,6-dianhydro-2,5-dideoxy-D-hexitol.

The present invention is directed to 5-sec-butyl-2-(2,4-dimethyl-cyclohex-3-enyl)-5-methyl-[1,3]dioxane and a novel process for making the same.

A process for the production of 1,4-butanediol and tetrahydrofuran by catalytic hydrogenation of dialkyl maleates includes the following steps: a) hydrogenating a stream of dialkyl maleate in a first stage of reaction over suitable catalysts to produce dialkyl succinate;b) further hydrogenating the dialkyl succinate in a second stage of reaction, by using a different suitable catalyst, for producing mainly 1,4-butanediol, together with gamma-butyrolactone and tetrahydrofuran as co-products. In both stages of reaction the conditions, as hydrogen/organic feed ratio, pressure and temperature, are such to maintain the reactors in mixed liquid/vapor phase.

Disclosed are methods of purifying (20R) and (20S) analogs of 2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 to obtain the (20R) and (20S) analogs in crystalline form. The method includes the steps of preparing a solvent of either diethyl ether or a mixture of 2-propanol and hexane, dissolving a product containing the (20R) and (20S) analog to be purified in the solvent, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals.

The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.

Disclosed are methods of purifying the compound (20R)-2-methylene-19-nor-24-difluoro-1α,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a solvent comprising hexane and 2-propanol, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals.

The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.

Disclosed are methods of purifying the compound (20R)-19-nor-24-difluoro-1α,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a solvent comprising hexane and 2-propanol, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals.

The present invention generally relates to a method for minimizing the formation of insoluble salts of phenoxy herbicides. The method comprises (1) mixing a compatibility agent, amine salts of phenoxy acid herbicides, and a chemical containing non-amine cations in a aqueous system to form a stable and non-nozzle plugging solution; and (2) application of said stable and non-nozzle plugging solution onto target plants.

A compound of the formula (1) wherein the substituents are as defined in claim 1, are useful as a pesticides.

Herbicidal injury caused by 6-trisubstituted phenyl)-4-amino-2-pyridinecarboxylates in wheat and barley is reduced with the use of low rates of cloquintocet.

The invention relates to the soybean variety designated 01045772. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01045772. Also provided by the invention are tissue cultures of the soybean variety 01045772 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01045772 with itself or another soybean variety and plants produced by such methods.

The invention relates to the soybean variety designated 01046169. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01046169. Also provided by the invention are tissue cultures of the soybean variety 01046169 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01046169 with itself or another soybean variety and plants produced by such methods.

The present invention provides an inbred corn line designated DC4016YD, methods for producing a corn plant by crossing plants of the inbred line DC4016YD with plants of another corn plant. The invention further encompasses all parts of inbred corn line DC4016YD, including culturable cells. Additionally provided herein are methods for introducing transgenes into inbred corn line DC4016YD, and plants produced according to these methods.

The present invention provides an inbred corn line designated HID3483, methods for producing a corn plant by crossing plants of the inbred line HID3483 with plants of another corn plant. The invention further encompasses all parts of inbred corn line HID3483, including culturable cells. Additionally provided herein are methods for introducing transgenes into inbred corn line HID3483, and plants produced according to these methods.

In an embodiment, the invention relates to the seeds, plants, and plant parts of canola variety SCV435009 and to methods for producing a canola plant produced by crossing canola variety SCV435009 with itself or with another canola variety. The invention also relates to methods for producing a canola plant containing in its genetic material one or more transgenes and to the transgenic canola plants and plant parts produced by those methods. This invention also relates to canola varieties or breeding lines and plant parts derived from canola variety SCV435009, to methods for producing other canola varieties, lines or plant parts derived from canola variety SCV435009 and to the canola plants, varieties, and their parts derived from use of those methods. The invention further relates to hybrid canola seeds, plants and plant parts produced by crossing the variety SCV435009 with another canola variety.

The invention relates to the soybean variety designated A1035446. Provided by the invention are the seeds, plants and derivatives of the soybean variety A1035446. Also provided by the invention are tissue cultures of the soybean variety A1035446 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety A1035446 with itself or another soybean variety and plants produced by such methods.

According to the invention, there is provided seed and plants of the hybrid corn variety designated CH715413. The invention thus relates to the plants, seeds and tissue cultures of the variety CH715413, and to methods for producing a corn plant produced by crossing a corn plant of variety CH715413 with itself or with another corn plant, such as a plant of another variety. The invention further relates to genetic complements of plants of variety CH715413.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

This disclosure is directed to fused tetracyclic pyrido[4,3-b>]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.